<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Some patients with haematological <z:hpo ids='HP_0002664'>neoplasms</z:hpo> have features which overlap between a <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and a <z:hpo ids='HP_0005547'>myeloproliferative disorder</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Two such patients are reported, both having sideroblastic erythropoiesis and <z:hpo ids='HP_0001894'>thrombocytosis</z:hpo> and one sequentially developing features of atypical <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath>, idiopathic <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> and <z:hpo ids='HP_0011009'>acute</z:hpo> megakaryoblastic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain>The prevalence of <z:hpo ids='HP_0001894'>thrombocytosis</z:hpo> among cases of refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with ring sideroblasts may be as high as 15-20% and has implications for choice of therapy </plain></SENT>
</text></document>